Erschienen in:
30.05.2018 | Editorial
Primary hyperparathyroidism in prostate cancer: guilty or not guilty?
verfasst von:
G. Mazziotti, S. Frara, A. Mosca
Erschienen in:
Endocrine
|
Ausgabe 2/2018
Einloggen, um Zugang zu erhalten
Excerpt
Skeletal health is a clinically relevant issue in patients with prostate cancer (PC) [
1‐
3]. Bone is the most common site of PC cell migration with up to 90% of patients with advanced disease having bone metastases [
4] with potential negative impact on quality of life and survival [
5]. Since the first description of the “seed and soil” hypothesis by Stephan Paget in 1889 [
6], several cellular signaling pathways, cytokines, chemokines, and adhesion molecules have been identified as players of cross-talking between PC cells and bone [
7] attempting to relate them either to metastases diagnosis or to patients’ prognosis (as prognostic factors) or to response to therapy (as predictive factors) [
8]. …